Alumis' lead clinical candidate, ESK-001, is a highly selective, next-generation oral TYK2 inhibitor that is designed to correct immune dysregulation across a spectrum of diseases driven by ...

SOUTH SAN FRANCISCO - Alumis Inc. (NASDAQ:ALMS), a biopharmaceutical company focusing on immune-mediated diseases, has announced the completion of its merger with ACELYRIN, Inc. As a result of the ...

Establishes leading clinical stage biopharma company with differentiated portfolio of therapies and strong balance sheetSOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc ...

SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune ...

SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune ...

Alumis is also developing A-005, a CNS-penetrant, allosteric TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases. Beyond TYK2, ...

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing thera Tuesday, 02 January 2024 12:17 GMT عربي ...

Alumis Inc., a clinical-stage biopharmaceutical company focused on therapies for immune-mediated diseases, announced that its stockholders approved all proposals necessary for its merger with ...

Alumis is currently developing ESK-001, a targeted oral treatment for patients with moderate-to-severe plaque psoriasis and systemic lupus erythematosus. Another candidate, ...

Alumis Inc. SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to ...

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize ...